# Oportun Financial Corp: financial statements, quarterly

OPRT · Nasdaq · CIK 1538716 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oprt.md) · [Financials](/companies/oprt/financials.md) · [Filings](/companies/oprt/filings.md) · [Insiders](/companies/oprt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oprt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.2](/filings/0001538716-24-000138.md) | [6.2 d](/filings/0001538716-25-000013.md) | [6.5](/filings/0001538716-25-000043.md) | [5.4](/filings/0001538716-25-000082.md) | [6.3](/filings/0001538716-25-000105.md) | [4.4 d](/filings/0001538716-26-000015.md) | [5.0](/filings/0001538716-26-000039.md) | [4.8](/filings/0001538716-26-000067.md) | [4.9](/filings/0001538716-25-000105.md) | [4.7 d](/filings/0001538716-26-000015.md) | [4.6](/filings/0001538716-26-000039.md) | [5.2](/filings/0001538716-26-000067.md) |
| Selling, general and administrative | $m | [11.9](/filings/0001538716-24-000138.md) | [20.2 d](/filings/0001538716-25-000013.md) | [11.8](/filings/0001538716-25-000043.md) | [22.0](/filings/0001538716-25-000082.md) | [13.0](/filings/0001538716-25-000105.md) | [6.4 d](/filings/0001538716-26-000015.md) | [7.4](/filings/0001538716-26-000039.md) | [9.8](/filings/0001538716-26-000067.md) | [10.5](/filings/0001538716-25-000105.md) | [6.3 d](/filings/0001538716-26-000015.md) | [7.0](/filings/0001538716-26-000039.md) | [6.0](/filings/0001538716-26-000067.md) |
| Income tax | $m | [(16.2)](/filings/0001538716-24-000138.md) | [(15.5) d](/filings/0001538716-25-000013.md) | [(4.0)](/filings/0001538716-25-000043.md) | [(18.1)](/filings/0001538716-25-000082.md) | [(9.5)](/filings/0001538716-25-000105.md) | [(4.8) d](/filings/0001538716-26-000015.md) | [3.4](/filings/0001538716-26-000039.md) | [3.2](/filings/0001538716-26-000067.md) | [9.0](/filings/0001538716-25-000105.md) | [3.2 d](/filings/0001538716-26-000015.md) | [1.2](/filings/0001538716-26-000039.md) | [7.1](/filings/0001538716-26-000067.md) |
| Net income | $m | [(21.1)](/filings/0001538716-24-000138.md) | [(41.8) d](/filings/0001538716-25-000013.md) | [(26.4)](/filings/0001538716-25-000105.md) | [(31.0)](/filings/0001538716-25-000105.md) | [(30.0)](/filings/0001538716-25-000105.md) | [8.7 d](/filings/0001538716-26-000015.md) | [9.8](/filings/0001538716-26-000067.md) | [6.9](/filings/0001538716-26-000067.md) | [5.2](/filings/0001538716-25-000105.md) | [3.4 d](/filings/0001538716-26-000015.md) | [2.3](/filings/0001538716-26-000067.md) | [8.5](/filings/0001538716-26-000067.md) |
| Diluted EPS | $ per share | [(0.55)](/filings/0001538716-24-000138.md) | not reported | [(0.68)](/filings/0001538716-25-000043.md) | [(0.78)](/filings/0001538716-25-000082.md) | [(0.75)](/filings/0001538716-25-000105.md) | not reported | [0.21](/filings/0001538716-26-000039.md) | [0.14](/filings/0001538716-26-000067.md) | [0.11](/filings/0001538716-25-000105.md) | not reported | [0.05](/filings/0001538716-26-000039.md) | [0.17](/filings/0001538716-26-000067.md) |
| Basic EPS | $ per share | [(0.55)](/filings/0001538716-24-000138.md) | not reported | [(0.68)](/filings/0001538716-25-000043.md) | [(0.78)](/filings/0001538716-25-000082.md) | [(0.75)](/filings/0001538716-25-000105.md) | not reported | [0.21](/filings/0001538716-26-000039.md) | [0.15](/filings/0001538716-26-000067.md) | [0.11](/filings/0001538716-25-000105.md) | not reported | [0.05](/filings/0001538716-26-000039.md) | [0.18](/filings/0001538716-26-000067.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [81.9](/filings/0001538716-24-000138.md) | [91.2](/filings/0001538716-25-000013.md) | [69.2](/filings/0001538716-25-000043.md) | [72.9](/filings/0001538716-25-000082.md) | [71.8](/filings/0001538716-25-000105.md) | [60.0](/filings/0001538716-26-000015.md) | [78.5](/filings/0001538716-26-000039.md) | [96.8](/filings/0001538716-26-000067.md) | [105](/filings/0001538716-25-000105.md) | [106](/filings/0001538716-26-000067.md) | [130](/filings/0001538716-26-000039.md) | [140](/filings/0001538716-26-000067.md) |
| Total assets | $m | [3,430](/filings/0001538716-23-000178.md) | [3,412](/filings/0001538716-25-000013.md) | [3,278](/filings/0001538716-24-000060.md) | [3,250](/filings/0001538716-24-000106.md) | [3,251](/filings/0001538716-24-000138.md) | [3,227](/filings/0001538716-26-000015.md) | [3,226](/filings/0001538716-25-000043.md) | [3,201](/filings/0001538716-25-000082.md) | [3,186](/filings/0001538716-25-000105.md) | [3,258](/filings/0001538716-26-000067.md) | [3,168](/filings/0001538716-26-000039.md) | [3,129](/filings/0001538716-26-000067.md) |
| Total liabilities | $m | [2,989](/filings/0001538716-23-000178.md) | [3,007](/filings/0001538716-25-000013.md) | [2,896](/filings/0001538716-24-000060.md) | [2,896](/filings/0001538716-24-000106.md) | [2,924](/filings/0001538716-24-000138.md) | [2,873](/filings/0001538716-26-000015.md) | [2,860](/filings/0001538716-25-000043.md) | [2,825](/filings/0001538716-25-000082.md) | [2,802](/filings/0001538716-25-000105.md) | [2,868](/filings/0001538716-26-000067.md) | [2,771](/filings/0001538716-26-000039.md) | [2,722](/filings/0001538716-26-000067.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [441](/filings/0001538716-24-000138.md) | [404](/filings/0001538716-26-000015.md) | [382](/filings/0001538716-25-000105.md) | [354](/filings/0001538716-25-000105.md) | [328](/filings/0001538716-25-000105.md) | [354](/filings/0001538716-26-000067.md) | [366](/filings/0001538716-26-000067.md) | [376](/filings/0001538716-26-000067.md) | [384](/filings/0001538716-25-000105.md) | [390](/filings/0001538716-26-000067.md) | [396](/filings/0001538716-26-000067.md) | [407](/filings/0001538716-26-000067.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [107 d](/filings/0001538716-24-000138.md) | [106 d](/filings/0001538716-25-000013.md) | [85.9](/filings/0001538716-25-000043.md) | [108 d](/filings/0001538716-25-000082.md) | [108 d](/filings/0001538716-25-000105.md) | [91.4 d](/filings/0001538716-26-000015.md) | [101](/filings/0001538716-26-000039.md) | [105 d](/filings/0001538716-26-000067.md) | [99.0 d](/filings/0001538716-25-000105.md) | [109 d](/filings/0001538716-26-000015.md) | [104](/filings/0001538716-26-000039.md) | [109 d](/filings/0001538716-26-000067.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.0](/filings/0001538716-23-000178.md) | [34.0](/filings/0001538716-24-000060.md) | [36.7](/filings/0001538716-24-000106.md) | [38.3](/filings/0001538716-24-000138.md) | [38.9](/filings/0001538716-25-000043.md) | [39.8](/filings/0001538716-25-000082.md) | [40.0](/filings/0001538716-25-000105.md) | [47.0](/filings/0001538716-26-000039.md) | [47.9](/filings/0001538716-26-000067.md) | [48.3](/filings/0001538716-25-000105.md) | [48.5](/filings/0001538716-26-000039.md) | [49.4](/filings/0001538716-26-000067.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,987,253 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001538716-26-000067.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.